Prosecution Insights
Last updated: May 29, 2026

Inovio Pharmaceuticals Inc.

17 pending office actions • 8 art units • 16 examiners • 0 of 17 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Portfolio Summary

17
Total Pending OAs
10
Non-Final OAs
7
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 17 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

11
Overdue
0
Due this week
4
Due this month
2
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 17 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (11)Due ≤ 30 days (4)Due ≤ 60 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
9
Medium (53%)
0
Easy (0%)
8
Unknown (47%)

Rejection Statute Mix

BucketCases
§103 only9 (53%)
No statute on record8 (47%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

13
Life Sciences
76% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
4
Mechanical / Eng
24% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

170 h
Manual time on pending OAs
34 h
Time saved (low, 20%)
59 h
Time saved (mid, 35%)
1.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
VU, QUYNH-NHU HOANG 2 68.2% +27.9%
BLUMEL, BENJAMIN P 1 70.7% +30.6%
BOESEN, AGNIESZKA 1 68.1% +21.9%
ZOU, NIANXIANG 1 64.3% +24.2%
GILL, RACHEL B 1 65.6% +27.7%
OSINSKI, BRADLEY JAMES 1 78.5% +11.3%
KIM, SUN U 1 78.5% +11.1%
JACKSON-TONGUE, LAKIA J 1 68.8% +20.4%
ALAWADI, SARAH 1 37.7% +38.2%
SALVOZA, M FRANCO G 1 69.0% +29.4%

Interview Candidates (11)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18503487 Vaccines For Human Papilloma Virus And Methods For Using The Same ZOU, NIANXIANG 138d overdue
18302522 METHOD AND DEVICE FOR MINIMALLY INVASIVE IN VIVO TRANSFECTION OF ADIPOSE TISSUE USING ELECTROPORATION KIM, SUN U 100d overdue
18656948 DNA ANTIBODY CONSTRUCTS FOR USE AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS BLUMEL, BENJAMIN P 80d overdue
18526819 DNA ANTIBODY CONSTRUCTS FOR USE AGAINST HIV BOESEN, AGNIESZKA 78d overdue
16804707 VARIABLE CURRENT DENSITY SINGLE NEEDLE ELECTROPORATION SYSTEM AND METHOD VU, QUYNH-NHU HOANG 37d overdue
18339387 INTRADERMAL INJECTION DEVICE VU, QUYNH-NHU HOANG 16d overdue
18468041 Vacuum-Assisted Treatment Device, and Related Systems and Methods OSINSKI, BRADLEY JAMES 9d
18060048 IN VIVO USE OF CHONDROITINASE AND/OR HYALURONIDASE TO ENHANCE DELIVERY OF AN AGENT JACKSON-TONGUE, LAKIA J 12d

Top Art Units

Art UnitApps
1671 4
3783 4
1672 3
1645 2
1777 1
1619 1
1643 1
1674 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18656948 DNA ANTIBODY CONSTRUCTS FOR USE AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS BLUMEL, BENJAMIN P 1671 Other Final Rejection 80d overdue Pending May 07, 2024
18526819 DNA ANTIBODY CONSTRUCTS FOR USE AGAINST HIV BOESEN, AGNIESZKA 1672 Other Non-Final OA 78d overdue Pending Dec 01, 2023
18503487 Vaccines For Human Papilloma Virus And Methods For Using The Same ZOU, NIANXIANG 1671 Other Final Rejection 138d overdue Pending Nov 07, 2023
18493133 LASSA VIRUS VACCINE AND USES THEREOF GILL, RACHEL B 1671 Other Non-Final OA 34d Pending Oct 24, 2023
18468041 Vacuum-Assisted Treatment Device, and Related Systems and Methods OSINSKI, BRADLEY JAMES 3783 §103 Non-Final OA 9d Pending Sep 15, 2023
18339387 INTRADERMAL INJECTION DEVICE VU, QUYNH-NHU HOANG 3783 Other Final Rejection 16d overdue Pending Jun 22, 2023
18302522 METHOD AND DEVICE FOR MINIMALLY INVASIVE IN VIVO TRANSFECTION OF ADIPOSE TISSUE USING ELECTROPORATION KIM, SUN U 1777 §103 Non-Final OA 100d overdue Pending Apr 18, 2023
18060048 IN VIVO USE OF CHONDROITINASE AND/OR HYALURONIDASE TO ENHANCE DELIVERY OF AN AGENT JACKSON-TONGUE, LAKIA J 1645 §103 Final Rejection 12d Pending Nov 30, 2022
18045575 TERT IMMUNOGENIC COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME ALAWADI, SARAH 1619 Other Final Rejection 34d Pending Oct 11, 2022
17813762 CANCER VACCINES AND METHODS OF TREATMENT USING THE SAME SALVOZA, M FRANCO G 1672 Other Non-Final OA 28d Pending Jul 20, 2022
17855349 Side-Port Injection Devices For Use With Electroporation, and Related Systems and Methods RODRIGUEZ, CRIS LOIREN 3783 §103 Non-Final OA 5d overdue Pending Jun 30, 2022
17771736 IMPROVED VACCINES FOR RECURRENT RESPIRATORY PAPILLOMATOSIS AND METHODS FOR USING THE SAME FOLEY, SHANON A 1671 §103 Non-Final OA 9d overdue Pending Apr 25, 2022
17720025 Methods of Inducing Immune Response Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern BUCKMASTER, MARLENE VRENI 1672 §103 Final Rejection 50d overdue Pending Apr 13, 2022
17474389 Checkpoint Inhibitor and Vaccine Combinations and Use of Same for Immunotherapy NATARAJAN, MEERA 1643 Other Non-Final OA 15d overdue Pending Sep 14, 2021
17188648 VACCINES WITH INTERLEUKIN-33 AS AN ADJUVANT JIANG, DONG 1674 §103 Non-Final OA 112d overdue Pending Mar 01, 2021
17063977 PD1 AND PDL1 ANTIBODIES AND VACCINE COMBINATIONS AND USE OF SAME FOR IMMUNOTHERAPY HINES, JANA A 1645 §103 Final Rejection 15d Pending Oct 06, 2020
16804707 VARIABLE CURRENT DENSITY SINGLE NEEDLE ELECTROPORATION SYSTEM AND METHOD VU, QUYNH-NHU HOANG 3783 §103 Non-Final OA 37d overdue Pending Feb 28, 2020

Managing Inovio Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month